HCV infection and transplant glomerulopathy and chronic humoral rejection

HCV infection and transplant glomerulopathy and chronic humoral rejection is a clinically important relationship in renal transplantation because hepatitis C virus infection is associated with both direct or indirect glomerular injury and an immunological environment that may favor chronic antibody-mediated damage. Across transplant cohorts, HCV-positive recipients show poorer graft survival, more proteinuria, and greater exposure to lesions such as transplant glomerulopathy and chronic allograft nephropathy, although the causal pathway is not uniform and may include immune-complex disease, endothelial injury, and heightened humoral immunity.

Definition and Clinical Setting

HCV infection is a systemic disease rather than a disorder confined to the liver. It can produce renal and autoimmune complications, including cryoglobulinemia and membranoproliferative glomerulonephritis, and these complications remain relevant after kidney transplantation. In renal allograft recipients, the central clinical signs are often proteinuria, impaired graft function, and histological evidence of glomerular or microvascular injury rather than a single distinctive syndrome.

The relationship must also be understood within the wider risk profile of transplantation. HCV-positive recipients have increased risks of cardiovascular disease, liver disease, serious infection, new-onset diabetes after transplantation, and graft loss. Consequently, an allograft may fail through several converging routes, with transplant glomerulopathy and chronic humoral rejection representing an important immunological pathway rather than an isolated viral complication.

Evidence for Graft Injury

Several comparative studies found worse graft survival among HCV-positive recipients. In a study comparing 488 anti-HCV-positive recipients with 2,877 seronegative recipients, the adjusted relative risk of graft loss was 1.53. An analysis from the Australian and New Zealand Dialysis and Transplant Registry likewise found poorer five-year graft survival in the anti-HCV-positive cohort, with an adjusted hazard ratio of 1.71 for graft failure. Graft loss in that cohort was more often attributed to glomerulonephritis, with an adjusted hazard ratio of 2.71, and chronic allograft nephropathy, with an adjusted hazard ratio of 1.87.

The broader evidence is not perfectly uniform. One prospective and two retrospective studies reported lower graft loss among HCV-positive recipients, although their findings did not reach statistical significance. Even so, a meta-analysis found anti-HCV antibodies to be an independent and significant risk factor for graft failure in four of eight included studies, with a relative risk of 1.56 and a 95% confidence interval of 1.35 to 1.80. The significant studies included most of the patients in the analysis, strengthening the conclusion that the association was not merely a small-study observation.

Proteinuria provides one clinical expression of this damage. HCV infection was identified as an independent risk factor for post-transplant proteinuria, which may arise from chronic allograft nephropathy, interstitial fibrosis and tubular atrophy, HCV-associated glomerulonephritis, or more than one process at the same time. In patients with proteinuria, chronic allograft nephropathy was the most frequent lesion, and nearly half of anti-HCV-positive patients in one pathological series had transplant glomerulopathy.

Transplant Glomerulopathy and Humoral Immunity

Transplant glomerulopathy is characterized clinically by progressive graft dysfunction and proteinuria and is closely associated with anti-human leukocyte antigen antibodies and antibody-mediated rejection. Some investigators have therefore proposed that the higher frequency of transplant glomerulopathy in HCV-positive recipients reflects an intensified humoral immune response rather than a direct effect of the virus alone. HCV-positive patients are frequently retransplant recipients, may have had renal disease for longer periods, and can carry a higher immunological risk, all of which complicate attempts to isolate the contribution of HCV.

The association has nevertheless appeared in pathological studies. HCV infection has been described as a risk factor for glomerulitis and transplant glomerulopathy, two lesions now closely linked with anti-human leukocyte antigen antibodies and antibody-mediated rejection. In one report, anti-HCV antibodies were significantly more prevalent among patients with transplant glomerulopathy than among those without it, at 33% compared with 1.9%. The proposed mechanism was endothelial injury caused directly or indirectly by HCV, possibly through cytokine release including interferon; over time, that injury could manifest clinically as transplant glomerulopathy.

The evidence therefore supports a layered model. HCV may contribute to endothelial and glomerular injury, while the recipient's humoral immune response may amplify or independently sustain microvascular damage. The result can resemble chronic antibody-mediated injury even when the initiating process is not exclusively alloimmune. This overlap explains why HCV remains an independent predictor of graft outcome in some protocol-biopsy studies, while also explaining why interpretation of individual biopsies requires caution.

HCV-Related Glomerular Disease in the Allograft

HCV-infected kidney and liver allograft recipients remain susceptible to immune-complex-mediated glomerulonephritis, as are nontransplanted patients. De novo membranoproliferative glomerulonephritis was reported in HCV-infected renal allograft recipients, and later work identified type II mixed cryoglobulinemia with an IgM-kappa monoclonal component in patients who developed de novo glomerulonephritis after transplantation. These observations connect viral infection, circulating immune complexes, and allograft injury even when the cryoglobulin burden is difficult to measure.

In transplanted patients, cryocrit levels are usually very low, generally below 5%, which can limit detection and characterization of cryoglobulins. HCV RNA may nevertheless be much more concentrated in the cryocrit than in serum, supporting a pathogenic role for HCV in the cryoglobulinemic process and suggesting activation of the classical complement pathway. The clinical picture may include hypertension, microscopic hematuria, proteinuria, renal dysfunction, and sometimes nephrotic syndrome.

Renal biopsy can show chronic damage in several compartments together with mesangial proliferation, double contours, and parietal immunoglobulin M and complement component 3 deposits. Because these findings can overlap with transplant-related lesions, electron microscopy may be necessary to distinguish membranoproliferative glomerulonephritis from transplant glomerulopathy. Thus, the same HCV-positive graft may be affected by immune-complex disease and chronic humoral injury, and the pathological distinction has consequences for how graft dysfunction is interpreted.

Management and Significance

The relationship between HCV and allograft injury begins before transplantation. Candidates should be screened for anti-HCV antibodies and active viremia, and active infection should prompt staging of liver disease. Liver biopsy remains the most reliable method for assessing advanced liver injury in this setting. Patients with established or decompensated cirrhosis should be referred for consideration of simultaneous liver-kidney transplantation, while patients on the kidney waiting list require ongoing surveillance because liver disease can progress during prolonged waits.

Patients who are HCV-positive while waiting should be evaluated regularly, and those with positive nucleic acid testing may be placed on hold and referred for hepatological assessment and possible treatment. A sustained virologic response achieved before transplantation is generally monitored at least annually with nucleic acid testing; relapse also warrants hold status and consideration of retreatment. The rationale for clearing HCV before transplantation includes the possibility of reducing post-transplant glomerular disease and avoiding the need for interferon after transplantation, when interferon treatment is associated with increased allograft rejection.

Yet transplantation remains the preferred form of renal replacement therapy for HCV-infected patients with end-stage renal disease when advanced liver injury does not preclude kidney-only transplantation. This benefit creates a difficult balance: HCV increases the risk of graft loss and may intensify chronic humoral injury, but remaining on dialysis can be more dangerous than accepting transplantation. Even the use of HCV-positive donor kidneys has been considered in HCV-positive recipients when it can shorten waiting time, particularly for patients who cannot receive, decline, fail, or tolerate antiviral therapy. The relationship between HCV, transplant glomerulopathy, and chronic humoral rejection therefore belongs to a larger chain of decisions in which viral control, immunological risk, waiting-list mortality, graft preservation, and access to scarce organs must be weighed together.